--- title: "Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE" type: "News" locale: "en" url: "https://longbridge.com/en/news/296582961.md" description: "Global Retirement Partners LLC initiated a new $4.34 million position in Pfizer Inc. (PFE) during the second quarter, purchasing 180,182 shares. This follows increased institutional buying by major firms like Vanguard, State Street, and Morgan Stanley in the fourth quarter. Pfizer recently reported earnings beating estimates, announced a quarterly dividend of $0.43 per share, and faces legal settlements regarding Depo-Provera while seeing positive sentiment around its cancer vaccine and obesity drug strategies." datetime: "2026-08-21T07:45:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296582961.md) - [en](https://longbridge.com/en/news/296582961.md) - [zh-HK](https://longbridge.com/zh-HK/news/296582961.md) generator: "portal-rs" --- # Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE Global Retirement Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 180,182 shares of the biopharmaceutical company's stock, valued at approximately $4,339,000. - The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. State Street Corp boosted its position in shares of Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock valued at $3,235,642,000 after acquiring an additional 1,184,728 shares during the last quarter. Morgan Stanley grew its holdings in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Finally, Norges Bank acquired a new stake in Pfizer during the fourth quarter worth about $1,830,986,000. Institutional investors and hedge funds own 68.36% of the company's stock. ## Pfizer Trading Down 1.5% NYSE PFE opened at $27.83 on Friday. The firm's 50-day moving average is $25.27 and its two-hundred day moving average is $26.24. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $158.62 billion, a P/E ratio of 36.62 and a beta of 0.34. - Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $0.78 earnings per share. Pfizer's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year. ## Pfizer Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer's dividend payout ratio (DPR) is presently 226.32%. ## Key Pfizer News - 2 Ways to Play the Big Pharma Patent Cliff Here are the key news stories impacting Pfizer this week: - Positive Sentiment: Pfizer shares benefited from renewed enthusiasm for cancer vaccines after Merck and Moderna reported positive melanoma-trial results for their personalized mRNA vaccine and Keytruda combination. The news has encouraged investors to reassess Pfizer’s own cancer-vaccine ambitions and broader mRNA exposure. Pfizer Stock Rises Wednesday: What's Going On? - Positive Sentiment: Pfizer’s obesity strategy remains a potential long-term catalyst. Investors are watching berobenatide, a possible monthly treatment intended to compete with leading GLP-1 drugs and help diversify revenue beyond legacy products. Pfizer's Obesity Push - Positive Sentiment: Pfizer’s high dividend yield and recent share performance are attracting income-oriented investors. Recent filings also indicate substantial hedge-fund buying, while unusually heavy call-option activity points to improving speculative sentiment. Yield Hunters and Hedge-Fund Buying - Neutral Sentiment: Pfizer completed a real-world study evaluating Ibrance in advanced breast cancer. The study’s completion could provide useful evidence for the product, but investors are awaiting the data and any commercial implications. Pfizer's Ibrance Study Update - Negative Sentiment: Pfizer is settling thousands of Depo-Provera lawsuits alleging a link to intracranial meningiomas. While a settlement program may reduce litigation uncertainty, it also highlights potentially significant financial exposure and keeps legal risk overhanging the stock. Why Is Pfizer Settling Thousands of Legal Claims? - Negative Sentiment: Investors remain focused on Pfizer’s patent cliff. New and acquired medicines may replace much of the revenue lost as older patents expire, but the transition leaves limited room for execution errors and raises concerns about longer-term growth. Pfizer Stock Is a Race Between New Drugs and Old Patents - Negative Sentiment: Merck’s deeper investment in personalized cancer vaccines raises the competitive bar for Pfizer and could make it harder for Pfizer to establish a leading position in this emerging market. Merck Raises the Stakes for Pfizer's Cancer Vaccine Ambitions ## Wall Street Analyst Weigh In A number of equities analysts have commented on the stock. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Finally, Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $28.28. **Get Our Latest Analysis on Pfizer** ## Pfizer Profile (Free Report) Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas. Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business. ## Featured Stories - Five stocks we like better than Pfizer - 3 Energy Stocks Raising Dividends as the Sector Surges - 5 Reasons the S&P 500 Could Keep Rallying Through Year-End - Walmart's Post-Earnings Drop Could Be a Buying Opportunity - The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Pfizer Right Now? Before you consider Pfizer, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list. While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [STT.US](https://longbridge.com/en/quote/STT.US.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [NUVL.US](https://longbridge.com/en/quote/NUVL.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [SPIN.US](https://longbridge.com/en/quote/SPIN.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) ## Related News & Research - [TCW Group Inc. Trims Stake in Pfizer Inc. $PFE](https://longbridge.com/en/news/296204181.md) - [Diversified Trust Co. Has $3.64 Million Stock Holdings in Pfizer Inc. $PFE](https://longbridge.com/en/news/296071353.md) - [Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/295997450.md) - [Pfizer Inc. $PFE Shares Bought by Farther Finance Advisors LLC](https://longbridge.com/en/news/296071335.md) - [Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims](https://longbridge.com/en/news/296430772.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**